Abstract

Background: Focal segmental glomerulosclerosis (FSGS) is a clinicopathological syndrome that presents with proteinuria, usually in the nephrotic range and evidence of histologic lesions of focal and segmental glomerular sclerosis with diffuse foot-process effacement. Recently, suPAR (soluble urokinase-type plasminogen activator receptor) was proposed as the potential circulating causative factor for primary FSGS. Objectives: We performed a cross-sectional study with the aim to determine whether there is a relationship between suPAR serum levels and primary FSGS. The secondary aim was to associate serum suPAR levels with kidney dysfunction. Patients and Methods: We enrolled a total of 90 patients with both suPAR serum levels and proteinuria. From these, 61 patients performed a renal biopsy. Results: The mean age was 49.8±17.2 years, 37 was females (60.7%) and 54 were Caucasian race (91.5%). FSGS was diagnosed in 30 patients (49%). suPAR levels were positive in 34 patients (55.7%) and negative in 27 (44.3%). Concerning the positive results, 17 patients had the histologic diagnosis of FSGS, which gives the test a sensibility of 28%. Concerning the negative results, 14 patients had a different histologic diagnosis other than FSGS, which gives the test a specificity of 23%. The predicted positive value was 50% and the predicted negative value was 52%. suPAR serum levels were not correlated with 24 hours proteinuria (P=0.5), but we found a positive correlation with C-reactive protein (P=0.037) and an inverse correlation with estimated glomerular filtration rate (eGFR) (P<0.001). Conclusions: We found that a positive suPAR test is not a marker of FSGS, but it can be a marker of podocyte and glomerular lesion, as it is inversely correlated with renal function in a cohort of proteinuric patients. Further studies are needed to further validate suPAR as a specific biomarker of glomerular damage.

Highlights

  • Focal segmental glomerulosclerosis (FSGS) is a clinicopathological syndrome that presents with proteinuria, usually in the nephrotic range and evidence of histologic lesions of focal and segmental glomerular sclerosis with diffuse foot-process effacement

  • Our results show that soluble urokinase plasminogen activator receptor (suPAR) test is not a marker of FSGS, but it can be a marker of podocyte and glomerular lesions in a cohort of proteinuric patients

  • We enrolled a total of 90 patients admitted to the nephrology department with both suPAR serum levels and proteinuria from January 2015 to December 2016

Read more

Summary

Introduction

Focal segmental glomerulosclerosis (FSGS) is a clinicopathological syndrome that presents with proteinuria, usually in the nephrotic range and evidence of histologic lesions of focal and segmental glomerular sclerosis with diffuse foot-process effacement. SuPAR (soluble urokinase-type plasminogen activator receptor) was proposed as the potential circulating causative factor for primary FSGS. Focal segmental glomerulosclerosis (FSGS) is a clinicopathological syndrome that was first described in an autopsy series [1] It presents with proteinuria, usually in the nephrotic range and evidence of histologic lesions of focal and segmental glomerular sclerosis with diffuse foot-process effacement [2,3]. A soluble form of uPAR (soluble urokinase-type plasminogen activator receptor) was proposed as being a potential causative circulating factor for primary FSGS. Elevated levels may be observed in malignant neoplasms [30]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call